174083-39-7

Usage

Uses

Used in Pharmaceutical Industry:
3,5-BIS(TRIFLUOROMETHYL)PHENYLACETYL CHLORIDE is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3,5-BIS(TRIFLUOROMETHYL)PHENYLACETYL CHLORIDE is utilized as a key intermediate in the production of agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection.
Used in Materials Science:
3,5-BIS(TRIFLUOROMETHYL)PHENYLACETYL CHLORIDE is employed as a versatile intermediate in the synthesis of advanced materials. Its properties contribute to the development of materials with improved performance characteristics for various applications, such as in coatings, adhesives, and polymers.
Used in Organic Synthesis:
As a highly reactive compound, 3,5-BIS(TRIFLUOROMETHYL)PHENYLACETYL CHLORIDE is widely used in organic synthesis for the production of complex organic compounds. Its ability to form diverse chemical bonds makes it a valuable tool in the creation of novel molecules with potential applications in various industries.

Upstream product

• 725-89-3 3,5-bistrifluoromethylbenzoic acid 
• 785-56-8 3,5-bis(trifluoromethyl)phenyl carboxylic acid chloride 
• 85068-33-3 3,5-bistrifluoromethylphenyl acetic acid 

Downstream Products

• 740806-08-0 4-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-buta-2,3-dienoic acid ethyl ester 
• 1080450-84-5 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-bromo-2-(1H-tetrazol-5-yl)-phenyl]-acetamide 
• 374794-58-8 (4S)-3-[3,5-bis(trifluoromethyl)benzeneacetyl]-4-(phenylmethyl)-2-oxazolidinone 

Relevant academic research and scientific papers

Urea-Based Multipoint Hydrogen-Bond Donor Additive Promotes Electrochemical CO2 Reduction Catalyzed by Nickel Cyclam

We report that a urea-based multipoint hydrogen-bond donor additive leads to an enhancement in activity for electrochemical CO2 reduction to CO catalyzed by Ni cyclam without altering this catalyst's high selectivity for CO2 versus p

Positional effects of second-sphere amide pendants on electrochemical CO2 reduction catalyzed by iron porphyrins

The development of catalysts for electrochemical reduction of carbon dioxide offers an attractive approach to transforming this greenhouse gas into value-added carbon products with sustainable energy input. Inspired by natural bioinorganic systems that fe

SULFONAMIDE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

BIARYL INHIBITORS OF THE SODIUM CHANNEL

The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns biaryl derivatives (e.g., compounds according to any of Formulas (I)-(XII) or Compounds (l)-(372) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

Palladium-catalyzed alkylation of vinyl oxiranes with substituted allenes. Direct access to bifunctionalized allylic alcohols

The first palladium-catalyzed alkylation of vinyl oxiranes with substituted allenes to form functionalized allylic alcohols is described. The reaction of activated allenes 5 with vinyl oxiranes 1 in the presence of catalytic amounts of Pd(PPh3)

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Quinolones as gonadotropin releasing hormone (GnRH) antagonists: Simultaneous optimization of the C(3)-aryl and C(6)-substituents

A series of 3-arylquinolones was prepared and evaluated for their ability to act as gonadotropin releasing hormone (GnRH) antagonists. A variety of substitution patterns of the 3-aryl substituent are described. The 3,4,5-trimethylphenyl substituent (23h) was found to be optimal. (C) 2000 Elsevier Science Ltd. All rights reserved.

Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyridopyridine

A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity.Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead 1a.Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyridopyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists.Among the compounds synthesized, N--7,8-dihydro-N,7-dimethyl-8-oxo-5-(substituted phenyl)-6-pyridopyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of 125I>BH-SP binding in human IM-9-cells) of 0.21-0.34 nM and ED50 values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg.These compounds exhibited significantly potent activity upon oral adiministration with ED50 values of 0.068-0.17 mg/kg.Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.